ADAM17 and myeloid leukemia: On the other hand, Romee et al. demonstrated that a disintegrin and ADAM17 regulate CD16 expression on NK cells.[24] Furthermore, Wiernik et al. showed that ADAM17 inhibition enhances the cytotoxic activity of NK cells against myeloid leukemia cells by the anti-CD16xanti-CD33 bispecific antibody.